Oncotelic Therapeutics, Inc.

📈 Chart on TradingView 💰 Financials on Finviz

$OTLC

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

Healthcare

Sector

Biotechnology

Industry

Vuong Trieu

CEO

Employees

$0.04

Current Price

$39.83M

Market Cap

52W Low$0.02

Current$0.0427.8% above low, 72.2% below high

52W High$0.11

Insider Activity Statistics

Aggregated buying and selling activity by time period

Period	Type	Insiders	Transactions	Value	Shares	Buy/Sell Ratio
1 week	Buys	1	2	$15,013.25	335,759	All Buys
1 week	Sells	0	0	-	-	All Buys
2 weeks	Buys	1	2	$15,013.25	335,759	All Buys
2 weeks	Sells	0	0	-	-	All Buys
1 month	Buys	1	2	$15,013.25	335,759	All Buys
1 month	Sells	0	0	-	-	All Buys
2 months	Buys	1	2	$15,013.25	335,759	All Buys
2 months	Sells	0	0	-	-	All Buys
3 months	Buys	1	2	$15,013.25	335,759	All Buys
3 months	Sells	0	0	-	-	All Buys
See activity going back 12 months — create a free account

Insider Transactions

Recent purchases and sales by company insiders

Date	Insider	Type	Shares	Price	Value	Actions
Jun 17, 2026	Trieu Vuong Director	Purchase	239,759	$0.04	$10,693.25	View Details
Jun 15, 2026	Trieu Vuong Director	Purchase	96,000	$0.04	$4,320.00	View Details
3 more transactions available — create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports

No upcoming earnings scheduled

Past Earnings

Historical earnings results

Apr 20, 2026

EPS

EstimatedN/A

ActualN/A

Revenue